GB2099300A - Antigens from parasites of the genus plasmodium - Google Patents
Antigens from parasites of the genus plasmodium Download PDFInfo
- Publication number
- GB2099300A GB2099300A GB8214624A GB8214624A GB2099300A GB 2099300 A GB2099300 A GB 2099300A GB 8214624 A GB8214624 A GB 8214624A GB 8214624 A GB8214624 A GB 8214624A GB 2099300 A GB2099300 A GB 2099300A
- Authority
- GB
- United Kingdom
- Prior art keywords
- antigen
- parasite
- antibody
- molecular weight
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000036639 antigens Human genes 0.000 title claims abstract description 122
- 108091007433 antigens Proteins 0.000 title claims abstract description 122
- 239000000427 antigen Substances 0.000 title claims abstract description 121
- 244000045947 parasite Species 0.000 title claims abstract description 40
- 241000224016 Plasmodium Species 0.000 title abstract description 4
- 210000001563 schizont Anatomy 0.000 claims abstract description 40
- 229960005486 vaccine Drugs 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 19
- 239000012528 membrane Substances 0.000 claims abstract description 17
- 230000036039 immunity Effects 0.000 claims abstract description 12
- 230000001939 inductive effect Effects 0.000 claims abstract description 11
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 48
- 108090000623 proteins and genes Proteins 0.000 claims description 48
- 239000012634 fragment Substances 0.000 claims description 31
- 210000003936 merozoite Anatomy 0.000 claims description 25
- 239000000463 material Substances 0.000 claims description 21
- 241000223960 Plasmodium falciparum Species 0.000 claims description 15
- 201000004792 malaria Diseases 0.000 claims description 15
- 210000003743 erythrocyte Anatomy 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 abstract description 3
- 230000000890 antigenic effect Effects 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 15
- 210000004379 membrane Anatomy 0.000 description 14
- 241000223830 Plasmodium yoelii Species 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 229920001184 polypeptide Polymers 0.000 description 10
- 210000004408 hybridoma Anatomy 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000012545 processing Methods 0.000 description 8
- 239000003599 detergent Substances 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 229920002684 Sepharose Polymers 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 239000007983 Tris buffer Substances 0.000 description 5
- 230000005875 antibody response Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000001114 immunoprecipitation Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 235000021251 pulses Nutrition 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 239000007857 degradation product Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000001502 gel electrophoresis Methods 0.000 description 4
- 238000010166 immunofluorescence Methods 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 238000012510 peptide mapping method Methods 0.000 description 4
- 229920002401 polyacrylamide Polymers 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000037029 cross reaction Effects 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- 230000002797 proteolythic effect Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 210000003812 trophozoite Anatomy 0.000 description 3
- BHNQPLPANNDEGL-UHFFFAOYSA-N 2-(4-octylphenoxy)ethanol Chemical compound CCCCCCCCC1=CC=C(OCCO)C=C1 BHNQPLPANNDEGL-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 241000223801 Plasmodium knowlesi Species 0.000 description 2
- RDFCSSHDJSZMTQ-ZDUSSCGKSA-N Tos-Lys-CH2Cl Chemical compound CC1=CC=C(S(=O)(=O)N[C@@H](CCCCN)C(=O)CCl)C=C1 RDFCSSHDJSZMTQ-ZDUSSCGKSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229960003964 deoxycholic acid Drugs 0.000 description 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 239000012133 immunoprecipitate Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000011218 segmentation Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 208000037369 susceptibility to malaria Diseases 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001360 synchronised effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 description 1
- HBOMLICNUCNMMY-KJFJCRTCSA-N 1-[(4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical class O=C1NC(=O)C(C)=CN1C1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-KJFJCRTCSA-N 0.000 description 1
- CSHOPPGMNYULAD-UHFFFAOYSA-N 1-tridecoxytridecane Chemical compound CCCCCCCCCCCCCOCCCCCCCCCCCCC CSHOPPGMNYULAD-UHFFFAOYSA-N 0.000 description 1
- HFGHRUCCKVYFKL-UHFFFAOYSA-N 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5h-pyrimido[5,4-b]indole Chemical compound C1=C2NC=3C(OCC)=NC(N4CCNCC4)=NC=3C2=CC=C1C1=CC=NC=C1 HFGHRUCCKVYFKL-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 244000203494 Lens culinaris subsp culinaris Species 0.000 description 1
- 235000014647 Lens culinaris subsp culinaris Nutrition 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000224017 Plasmodium berghei Species 0.000 description 1
- 206010035500 Plasmodium falciparum infection Diseases 0.000 description 1
- 241000223829 Plasmodium vinckei Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108010019965 Spectrin Proteins 0.000 description 1
- 102000005890 Spectrin Human genes 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108010046516 Wheat Germ Agglutinins Proteins 0.000 description 1
- MJOQJPYNENPSSS-XQHKEYJVSA-N [(3r,4s,5r,6s)-4,5,6-triacetyloxyoxan-3-yl] acetate Chemical compound CC(=O)O[C@@H]1CO[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O MJOQJPYNENPSSS-XQHKEYJVSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 244000000056 intracellular parasite Species 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000011206 morphological examination Methods 0.000 description 1
- AYOOGWWGECJQPI-NSHDSACASA-N n-[(1s)-1-(5-fluoropyrimidin-2-yl)ethyl]-3-(3-propan-2-yloxy-1h-pyrazol-5-yl)imidazo[4,5-b]pyridin-5-amine Chemical compound N1C(OC(C)C)=CC(N2C3=NC(N[C@@H](C)C=4N=CC(F)=CN=4)=CC=C3N=C2)=N1 AYOOGWWGECJQPI-NSHDSACASA-N 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- -1 polyoxyethylene Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
- C07K16/205—Plasmodium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Protection inducing antigens of parasites of the genus Plasmodium are described. The antigens have an apparent molecular weight of 1.8 to 2.5 x 10<5> and are associated with the membranes of the erythrocytic schizont forms of the parasite. The antigens may be incorporated into vaccines and used for the inducing of immunity into susceptible vertebrate hosts including humans. Methods for the preparation of the antigens are also described.
Description
SPECIFICATION Protozoal antigen The present invention relates to antigenic mater
ial, to vaccines containing it and to the use thereof to
provide immunity to malaria. The malaria parasites are protozoa belonging to the genus Plasmodium .
Part of their complex life cycle involves cyclic asexial replication within the erythrocytes of the vertebrate
host, giving rise to the symptoms of the disease
known as malaria. The vertebrate host may, in turn, exhibit a protective immune response which is effective against the blood-borne parasites. It is implied, therefore, that the blood forms synthesize antigens which elicit the production of specific, protective
antibodies in the infected or immunized host
During the asexual erythrocytic cycle of replication, free parasites (merozoites) recognize and attach specifically to the surface of erythrocytes, and then invade them byinvagination of the plasma mem
brane. The infected erythrocyte is known as the trophozoite. During the intadellular differentiation of the parasite the nucleus undergoes repeated divisions, to form the schizont.Nuclear division is followed by segmentation of the cytoplasm to form a number of uninucleate intraerythrocytic merozoites.
Upon lysis of the schizont membranes, the merozoites are released into the plasma and may attach to, and invade, fresh host erythrocytes.
Immunity to malaria is believed to be mediated by antibodies specific for parasite antigens associated with the schizont and/or merozoite forms of the parasite (see for example Cohen, Proc. R. Soc. London B, 1978,203; 323-345; Freeman and Parish, Exp.
Parasitol, 1981,52, 18-24).
A number of parasite antigens with the schizont membrane have been detected by crossed immunoelectrophoresis of solubilised schizont material against hyperimmune serum (see for example
Deans, Dennis and Cohen, Parasitology, 1978,77 333-344; Schmidt-Ullrich, Wallach and Lightholder,
J. exp. Med. 1979, 150,86-99). In particular the latter group have detected 3 antigens from Plasmodium knowlesi schizont membrane of molecular weight 65,000,90,000 and 125,000. These antigens are precipitated byP.knowlesi and P. falciparum immune serum.The available data on P.knowlesi and P.falciparum do not allow definite conclusions asto the developmental stage(s) at which parasite specific antigens are immonogenic or whether the antigens detected are the ones involved in protective immunity (Schmidt-Ullrich et a/ "The Host-lnvader Interplay", 1980, H. Van den Bossche ed., Elsevier/North Holland, Amsterdam, 117-120).
Schizont antigens ofP.falciparum have also been described (Kilejian, Proc. Nat. Acad. Sci. 1980,77, 3695-3699; J. exp. Med., 1980, 151,1534-1538; Perrin et.al. Trans. Roy, Soc. Trop. Med. Hyg. 1981,75, 163-165). None of these antigens have been purified
or shown to be protective antigens.
Antigens derived from schizont membranes and having moleular weights of up to 200,000 have also been referred to in the literature (Freeman et alThe
Host-lnvader Interplay, H. Van den Bossche, Ed.,
Elsevier/North Holland Biochemical Press 1980, 121-124) but the only antibody described, a monoclonal antibody specific for these antigens was shown not to provide passive immunity.
We have now surprisingly found that an antigen recognised by the aforementioned antibody and originating from a schizont membrane is capable of generating protection against malaria and such an antigen associated with schizont forms of Plasmodium parasites has now been isolated and defined.
The antigen so identified is a protection-inducing proteinaceous antigen of parasites of the genus
Plasmodium having the following characteristics: (i) a molecular weight in the range of 1.8 x 105 to
2.5x105; (ii) associated with the membranes of the eryt
hrocytic schizont form of the parasite; and
merozoite forms of the parasites; and (iii) is processed intraerythrocytically to discrete
fragments possessing the same antigenic
properties, and in which the antigen, or the discrete fragments thereof, are associated with the surface membrane of the merozite form of the parasite, and functional derivatives thereof.
These antigenic proteins are known to occur in a numberofmurine malaria protozoa such asPlasmodium yoelii, P. berghei and P. vinckei spp. and in primate malaria parasites, in particularP. fal- ciparum.
By "molecular weight" is meant the apparent molecular weight as determined by polyacrylamide gel electrophoresis and standard molecular weight markers. The molecular weight of the antigenic proteins of the invention may thus be conveniently determined by the techniques described by U.K.
Laemmli, Nature, 1970,227, 680485. Convenient standard molecular weight markers include, for example, spectrin heterodimer (2.2 x 105 molecular weight and 2.4 x105 molecular weight).
The term 'associated' as used herein refers not only to proteinaceous antigenic material originating from the schizont or merozoite forms of malaria parasites but to antigenically identical material of similar or identical amino acid sequence deriving from any other source.
The antigens of the present invention are synthesised only during the later stages of the parasite's intracellular development. Thus forP. falciparum the onset of synthesis of this antigen co-incides with the start of schizogeny and continue right through until the end of the intracellular stage.
It has been found that a characteristic of the parent antigen is that, no matter the parasite from which it derives, it is processed intraerythrocyticallyto dis creetfragments of lower molecularweightwhich possess the same antigenic properties. The moleculay weight of these fragments varies with that of the
The drawings originally filed were informal and the print here reproduced is taken
from a later filed formal copy.
particular parent antigen but it has been found that
the major fragments have molecularweightswhich
are respectively 0.3 - 0.4 x 105; 0.7 - 0.8 x 105; 1.0 - 1.4 X 104 lower than that of the parent antigen.
In synchronised cultures of P. falciparum the pro
cessing is not a co-translational event, but appears
to co-incide with merozoite maturation or release, at
the end of the intraerthrocytic development cycle. It
is likely that discrete fragment(s) ratherthan the
antigen itself are on the surface of merozoites.
It will be appreciated by one skilled in the art that the benefit of the immunogenic properties of the antigens above will be obtained not only from the parent antigens themselves but also immunogenic fragments thereof, including those generated intraerythrocytical ly, and materials incorporating the parent antigens or fragments thereof. All such materials are referred to herein as "functional dervatives".
The antigen proteins may be prepared by any method known in the art forth preparation of such methods comprise either isolation of theantigenic protein from the parasite or chemically or biologically reproducing the antigenic protein.
In one such method the antigenic proteins may be isolated from the schizontformsofthe parasite by means of monoclonal antibodies specific for the antigens of the invention. The technique of antigen separation by means of monoclonal antibodies has not previously been applied to the purification of malaria antigens.
There is thus provided a method for the preparation of an antigenic protein as defined herein which comprises the steps ofr (i) solubilising erythrocytes containing the schiz
one forms of a Plasmodium parasite; (ii) contacting the solubilised material with a
monoclonal antibody specific for the desired
antigenic protein to provide an antibody anti
gen complex; and (iii) recovering the antigenic protein from the anti
body - antigen complex.
There is also provided an antigenic protein as defined herein when prepared by the above defined method. The schizonts may be solubilised by any method known in the art for effecting such solubilisation. Suitable conditions which solubilise parasite material without extensive proteolysis and denaturation are employed. In particular they may be solubilised by contacting them with a detergent, which may be of the ionic or non-ionic type although non-ionic detergents are preferred. Examples of such detergents include Nonidet P40, Triton X-100, Brij 99 (registered Trade Marks, manufactured respectively by Shell, Rohm and Haas and ICI) and a polyoxyethylene (12) tridecyl ether detergent as known
Renex30 (Registered Trade Mark, manufactured by
Honeywell Atlas Limited). Detergent is added to a final concentration of between 0.01% and 5% viv.
Monoclonal antibodies for use in the method maybe prepared by any method known in the art for their production (see for example Milstein, Scientific
American 1980,243 (4), 56-64). In such a method a mouse is immunised against the parasite concerned, in this case a malaria parasite for example by infec
tion with a rodent malaria parasite. Lymphocytes,
each ofwhich will have the independent capacity to
make an antibody that recognises a different antigen
determinant, are then isolated and fused with mouse
myeloma cells to provide a "hybridoma". Each hyb
ridoma will be capable of expressing the antibody of
its parent lymphoyte and of being cioned.Screening
of individual hybridomas provides one or more cell
lines expressing the antibody, a monoclonal anti
body, specific for the antigenic determinant of inter
est and the cell-line then used to generate large
quantities of the monoclonal antibody which may then be used to separate and purifythe antigenic determinant of interest. Antibodies specific for the antigens defined herein may be readily identified by simple, well known testing procedures.
The monoclonal antibody is suitable bonded to an inert support material, for example Sepharose (Trade Mark), and the solubilised material passed through the support containing antibody. This may conveniently be effected by means of a column.
The antigenic protein may be recovered from the antibody-antigen complex by disruption ofthe complex. The conditions for effecting this are well known in the art. Suitable conditions which preserve the immunogenicity of the protein include washing with diethylene at high pH, for example pH 11.5 in the presence of a suitable detergent.
The antigens described above may be incorporated into a vaccine for inducing immunity to Malaria in susceptible veterbrate hosts at risk of becoming infected by parasites of the genusPlasmodium. For this purpose the antigen proteins may be presented in association with a pharmaceutically acceptable carrier. The antigenic proteins may be used singly or in combination with other functional derivatives thereof or with other proteins which will provide protection against malaria.
In a further aspect there is provided a vaccine for inducing immunity to Malaria which comprises an antigen as hereinbefore defined or a functional derivative thereof in association with a pharmaceutically acceptable carrier.
Pharmaceutically acceptable carriers, in this intance, are liquid media suitable for use as vehicles to introduce the antigen into the patient. An example of such a carrier is saline solution. The antigenic protein may be in solution or suspended as a solid in the carrier, or it may be soiubilised by the addition of pharmaceutically acceptable detergent.
The vaccine may also comprise an adjuvantfor stimulating the immune response and thereby enhancing the effect of the vaccine. Convenient adjuvants for use in the present invention include
Freunds complete adjuvant and more particularly, saponin, Cor'nebactreium parvum (coparvax) and aluminium hydroxide our a mixture of these or other known adjuvants.
Conveniently the vaccines are formulated to contain a final concentration of antigenic protein in the range of from 0.2 to 5 mg/ml, preferably 0.5 to 2 mg/ml, most preferably 1 mg/ml. After formulation the vaccine may be incorpoated into a sterile con tainerwhich is then sealed and stored at a low temperature, for example 4"C, or may be freeze dried.
In order to induce immunity in veterbrate hosts to malaria one or more doses of the vaccine suitably formulated may be administered. It is recommended that each dose of 0.1 to 2 ml preferably 0.2 to 1 ml, most preferably 0.5 ml of vaccine.
There is in a further aspect provided a method for inducing immunity to malaria in susceptible veterbrate hosts, comprising the administration of an effective amount of a vaccine, as hereinbefore defined, to the host
The vaccines may be administered by any conventional methodforthe administration of vaccines including oral and parenteral (eg. subcutaneous or intramuscular) injection. The treatment may consist of a single dose of vaccine or a plurality of doses over a period of time.
The following Examples serve to illustrate the invention but are not intended to limit it in any way.
EXAMPLE 1 Derivation ofHybridoma Line for P.
yoelii antigen
Spleen cells from two P. yoelii- immune BALBIc mice were fused with P3-NS1 /1 -Ag4-1 myeloma cells in the presence of polyethylene glycol (by the general method of Galfre, et. al., Nature, 1977,266, 550-552). The cells were dispensed into 144 tissue culture wells in 2 ml volumes of HAT selective medium (Littlefield, Science, 1964, 145,709-710) using RPMI 1640 medium supplemented with 10% foetal calf serum as a base. After 10 days the culture supernatants were tested for P.yoe/ii-specific antibody by indirect immunofluorescence (IIF). Of 143 cultures tested, 38 were positive. Culture number 1 contained an antibody specific for an antigen associated with schizonts but absent from ring-forms and trophozoites.A cloned hybridoma cell line was produced from this culture by growing colonies derived from single cells in semi-solid agar overlayed with medium. The cloned hybridoma line continued to secrete its unique antibody, was designated WIC 25.1. and has been deposited at the Institute Pasteur under the number 1-160 on 16 July 1981. The hybridoma line was further grown as an ascites tumor in BABBLE mice, and ascitic fluid and serum from these mice contained abour 10 mg/ml of the monospecific antibody. A second hydridoma line, WIC 45.1 secretes an antibody specific for the same antigen as antibody 25:1, with the difference that it appears to recognise only the antigen and fragments larger than 0.9 x 105 molecular weight.
EXAMPLE2 Preparation of Antigen from P. yoelii
Blood forms of Plasmodium yoelii were grown in
CD-1 mice to 80-90% parasitaemia and the erthrocytes were harvested and solubilised. The cells were solubilised by lysis at4 C in a buffer of 50mM Tris, SmMethylenediamine tetraacetate (EDTA), 1% Nonidet P40 pH 8.0 containing 1 mM phenylmethyl sulphonyl fluoride (PMSF), 0.1 mM tosyl-L-lysine chloromethyl ketone (TLCK), 5mM ethyleneglycolbis-(amino ethyl ether)N,N'-tetraacetate (EGTA) and 5mM iodoacetamide to inhibit proteolytic activity.
The lysed cells were centrifuged at 100,000 g and the supernatant, containing the erythrocyte soluble proteins and some membrane proteins, together with approximately 70% of the parasite proteins (as estimated from the proportion of35S-methionine label in this fraction after an in vitro incorporation) collected.
Immunoglobulin from the ascites fluid of mice containing hybridoma line WIC 25.1 was purified by binding to Protein A- Sepharose and a single step elution at pH 3.0. The immunoglobulin fraction was coupled to cyanogenbromide activated Sepharose, using 10 mg immunoglobulin/ml swollen gel. The imm unoabsorbant was extremely washed, packed into colums and equilibrated with 10mM Tris, 1mM EDTA, 1 mM EGTA, 1% NP40 pH 8.0.
The supernatant obtained as described above was passed through the immunoabsorbant equilibrated with 10mM Tris, 1 mM EDTA, 1 mM EGTA, 1% NP40 pH 8.0 and washed through with this buffer. Non specifically bound material was removed by washing (5 column volumes) with this buffer containing 0.5M NaCI. The column was then washed with a buffercontaining 10mMTris, 1mM EDTA, 1mM EGTA, 0.1% NP40 pH 8.0. Specific elution was achieved with 50mM diethylamine, 0.1% NP40 pH 11.5.
The eluted material was subjected to a second cycle of immunoabsorbant chromatography. The specific eluate was dialysed against a buffer containing 10mM Tris, 1mM EDTA, 1mM EGTA, 0.1% NP40 pH 8.0. The sample was applied to the column which had been reequilibrated in this buffer, and washed through with 10mM Tris, imM EDTA, imM EGTA, 0.5% sodium deoxycholate pH 8.2. The retained material was eluted with 50mM diethylamine, 0.5% sodium deoxycholate pH 11.5. The eluate was concentrated and dialysed to provide the antigen.
EXAMPLE3 Biochemical Characterization of the
Antigen and its proteolytic degrada
tion fragments from P. yoelii
Antigen was labelled by incorporation of 35S- methionine into the protein by incubating parasitized cells for 2-3 hours in a medium containing this amino acid at high specific activity, the labelled antigenic protein was obtained by immunoprecipitation with the monoclonal antibody 25.1 and Protein A bearing Staphylococcus aureus cells to precipitate the immune complex. This material was subjected to
SDS gel electrophoresis and the antigen behaved as species of 2.30 x 105 apparent molecular weight. In addition, a series of degradation products possessing the antigenic determinantwas detected. The principle fragments had apparent molecular weights of 1.97, 1.60, 1.51, 1.26, 0.90, 0.56 and 0.28 x 105.
Minor degradation products of apparent molecular weights2.20,2.13, 1.90, 1.80, 1.74, 1.48, 1.18,1.12 and 1,04 x 105 were also present. The antigen purified by immunoabsorbant column chromatography described in Example 2, displayed a pattern of degradation products identical to that of the immunoprecipitated 35S-methionine labelled material.
The nature of the relationship of the polypeptides was revealed by peptide mapping of the major
polypeptides and by pulse-chase labelling of P. yoelii schizonts. Homology between the amino acid sequences of the major polypeptides was clearly shown by two dimensional chymotryptic peptide mapping of 35-S-methionine-labelled polypeptides immunoprecipitated by antibody 25.1 and by limited proteolysis peptide mapping in SDS polyacrylamide
gels of purified material which had been iodinated
using '251-iodine. P. yoelii schizonts were incubated
for 10 minutes in the presence of high specific activ
ity 35S-methionine which was then chased with non
radioactive methionine. At various time intervals
after labelling samples were solubilised and
immunoprecipitated with antibody 25.1.The label
was intially incorporated into the 2.30 x 105 MW
polypeptide, then during further incubation it
sequentially appeared in the smaller iolypeptides,
with a concomitant reduction in the amount of label
remaining in the 230,000MW component. Thus the
native antigen recognised by antibody 25.1 is a 2.3 x
105 molecular weight protein and the smaller
polypeptides are proteolytic fragments of it, each
retaining the antigenic determinant recognised by the monoclonal antibody. In vitro, degradation of the
native protein commenced soon after its synthesis, and was extensive after7 hours. The results indicate that the degradation occurred during incubation of the intact schizonts ratherthan after cell lysis and solubilisation.
The isoelectric point of the antigen and some of its fragments were determined using a 2-dimensional gel electrophoresis system based on that described byO'Farrell (J.Biol. Chem.250:40074021, 1975) but using either a polyacrylamide or a mixed agarose/polyacrylamide gel in the first dimension. When the pH gradient was generated using pH 3-10 ampholines, the antigen and its fragments had the following approximate isoelectric points; 2.3 x 105
MW, pH 5.35.7; 1.6 x 105 MW, 5.2-5.5; 1.5 x 105 MW, 5.25.5; 0.9 x MW, 6.05.7; 0.56 x 105,5.2-5.4 and 0.30 x 0 MW, 5.0-5.3. The arrangement of the fragments according to isoelectric point was always 0.28 < 0.56 < 1.5, 1.6 < 2.3 < 0.9 x 105 MW.
Standard tests employing periodic acid-Schiffs staining and '251-iodinated Concanavalin A lectin binding to the protein in polyacrylamide gels both suggested that the protein was not glycosylated.
The lack of glycosylation was confirmed by inability to specifically bind the elute the protein from lentil lectin-Sepharose and wheatgerm agglutinin
Sepharose, and by the absence of any effect on the size of the protein when synthesised by the parasite in the presence oftunicamycin, a specific inhibitor or protein N-glycosylation.
EXAMPLE4 Localisation of the antigen associated
with P. yoelii By IIF using acetone-fixed cells the antigenic portein was localised to the membrane of schizonts and merozoites. Neither antibody 25.1 nor poly-valent antiserum raised against the purified protein reacted with the surface of unfixed intact schizont in suspension. The protein was not labelled by lactoperoxide catalysed iodination of intact schizonts, but was labelled by this technique when the cells were first solubilised by addition of 0.01% (v/v) Nonidet P 40.
Furthermore the addition of trypsin (at 5 uglm I) to the medium did notmodifythe processing of the
protein observed during the in vitro incubation of
parasitised cells, described in Example 3. It is thus considered that the protein is not exposed on the
outer surface of the host cell membrane nor localised at the inner surface of this membrane. The IIF
pattern produced by antibody 25.1 suggests that the 2.30 x 105 MW protein of Example 2 is associated specifically with the plasma membrane of the developing intracellular parasite, rather than with the membrane of the host erythrocyte.This interpretation is supported by further evidence provided using a double labelling immunofluorescence technique in which acetone fixed schizonts were incubated with a mixture of antibody 25.1 (a mouse immunoglobulin) and rabbit anti-mouse red cell antiserum. The slides were washed then incubated sequentially with rhodamineconjugated goat anti- rabbit IgG antiserum and with FlTC-conjugated rabbit anti-mouse IgG antiserum. Upon examination it was noted that the P. yoelii schizont antigen (traced with FITC) was localised at a membrane distinct from, and enclosed within, the host red cell membrane (traced with rhodamine).
In early schizonts, prior to the information of the residual body, the antigen appearsto be localised at a spherical membrane enclosing the parasite, but the following segmentation and formation of the residual body, the membrane appears to surround individual merozoites. Thus the 2.3 x 105 MW protein (and/or proteolytic derivatives of it) is evenly distributed on free merozoites as well as being associated with schizonts.
In the IIF test with free merozoites in suspension, antibody 25.1 gave a positive florescense indicating that the antigen is on the surface of the merozoites.
EXAMPLES immunisation of mice with an antigen ofPlasmodium yoelii, purified using
monoclonal antibody25. 1: antibody
response
Groups of 5 BALBIc mice were immunised with the antigenic protein obtained from Example 2 or with control preparations according to the following schedule:
Group 1: 50,ug antigen 25.1 emulsified in Freund's
Complete Adjuvant (FCA) and injected
intraperitioneally (i.p.) in a volume of 0.2
ml on day 0.
20 pug antigen 25.1 suspended in 0.2 mis
normal mouse serum and injected
intravenously on day 26.
25,ag antigen 25.1 suspended in saline
and injected i.v. on day 39.
Group2: FCA only, given i.p. on day 0 NMS only, given i.v. on day 18
Saline only, given i.v. on day 42.
On day 49, serum samples were taken for titration and examination by indirect immunofluorescence (I IF). The results are shown below.
Group Mouse llF titre antiserum specificity 1 1 > 1:5120 schizonts and merozoites
2 > 1:5120 schizonts and merozoites
3 > 1:5120 schizonts and merozoites
4 > 1:5120 schizonts and merozoites
5 > 1:640 schizonts and merozoites 2 1 < 1:40 - 2 < 1:40
3 < 1:40 - 4 < 1:40 - 5 < 1:40 - The pattern of fluorescent staining using the serum from the mice immunised with antigen 25.1 was indistinguishable from that produced using monoclonal antibody 25.1. Staining was restricted to the schizont and merozoite forms of P. yoelii. This result confirmed the purity and immunogemic nature of antigen 25.1 prepared as described in Example 2.
EXAMPLE6 Immunisation ofmice with an antigen
ofPlasmodium yoelii, purified using
monoclonal antibody 25. 7: protection
against challenge infection
Groups of 5 BALBIc mice were immunised with the antigenic protein obtained from Example 2, or with control preparations according to the following schedule:
Group 1: 12 g antigen 25.1 emulsified in FCA and
injected i.p. in a volume of 0.2 mls on day
0.
12,ag antigen 25.1 in FCA i.p. on day 35.
20 clog antigen 25.1 in 0.1 ml saline i.v. on
day 50.
Group 2: 2,ag antigen 25.1 in FCA i.p. on day 0.
2,ug antigen 25.1 in FCA i.p. on day 35.
20 pug antigen 25.1 in 0.1 ml saline i.v. on
day 50.
Group3: Saline in FCA i.p. on day 0.
Saline in FCA i.p. on day 35.
0.1 ml saline given i.v. on day 50.
On day 60, serum samples were taken for IIF titration of antibody, and for analysis by immunoprecipitation. on day 61 all mice were challenged i.v. with 104
P. yoelii YM-parasitised erythrocytes. The antibody response of the groups on immunised mice are given in Table 1. The results demonstrate that under the conditions used, immunisation with 12,(b9 of antigen 25.1 was more effective in inducing an antibody response than was immunisation with 2 clog of antigen 25.1.
Table 1: Antibodyresponse ofmiceimmunised with antigen 25.1
Group IIF titre antiserum specfficity 1 > 1:10240 schizonts and merozoites 2 > 1:5120 schizonts and merozoites 3 < 1:40 nonspecific
The protection against challenge with P. yoelli provided to each group shown in Figure 1. The results show that the group with the higher antibody titre were more effectively protected against challenge.
The control group of mice all died within 8 days of challenge. All mice immunised with antigen 25.1 survived.
The antigen specificity of serum from the immunised mice was checked by immunopresipitation which demonstrated that the antibody response was directed against the 230,000 m.w. schizont antigen (and its degradation frangments) used for immunisation.
EXAMPLE7 Identification of the Antigen from P.
falciparum
A schizont-enriched fraction of erythrocytes, parasitised with P. falciparum prepared by centrifugation through a layer of Percoll, was labelled with 35S- methionine during a period of 2 hours. The cells were harvested and solubilised by lysis at4 as described in Example 2. After centrifugation the supernatant was used for immunoprecipitation with an antibody specific for P. falciparum and derived from a hybridoma prepared by the method of Example 1. The specific precipitate was subjected to SDS gel electrophoresis and the antigen behaved as a species of 1.95 x 105 apparent molecular weight. In addition, a number of discrete degradation products were observed.The principle fragments had molecular weights of 1.53, 1.50 and 0.83 x 105 and additional minor fragments of 1.12, 1.10 and 1.08 x 105 molecu larweightwere also present.
The identification of the 1.95 x 105 molecular weight component as the primary protein, from which the specific fragments were subsequently derived, was confirmed by labelling the cells for a short period of 20 minutes. Immunoprecipitates from extracts of this material using the P. falciparum antibody contained all of the 35S-methionine label in the 1.95 x 105 molecular weight antigen.
This antigen (and its specific fragments) is strongly represented in the material recognised by human immune serum toP. falciparum as assessed by immunoprecipitation and SDS gel electrophoresis.
The amino acid sequence relatedness of the major fragments and the 1.95X105 M.W. species was confirmed by peptide mapping of the 355-methionine- containing peptides. The isoelectric points of the antigen and its fragments were determined as approximately 5.8(1.95X105), 5.2(1.53 and 1.50X105), 6.0(1.1 0X1 0'), and 6.2-6.5(0.83X105).
Example 8 Preparation of antigen from P. fat- ciparum
P. falciparum parasites grown in culture in human erythrocytes, were harvested and solubilised, as described in Example 2. The solubilised material was passed down a column of Sepharose coupled with immunoglobuiin obtained from the ascites fluid of mice containing hybridoma line WIC 89.1. When the column was washed and eluted with 50 mM dieth ylamine,0.1%NP40, pH 11.5, as described in Example 2 the eluate contained predominantly the 195 x 105
MW antigen and the 0.83 x 105 MW fragment.
Example 9 Synthesis and processing ofthe antigen
from P. falciparum
The synthesis and processing of the protein during the intracellular development of the parasite was investigated during one 48 hour cycle in an in vitro culture of P. falciparum which had been synchronised by two treatments with sorbitol 33 hours apart.
The stage of development was monitored by morphological examination of Giemsa stained parasites, every 3 hours after the second sorbitol treatment.
only ring forms were observed for the first 12 hours, afterwhichtimetrophozoitesbegunto appear and were present maximally at 24 hours. Schizonts were first observed at27 hours and predominated at39 hours. At 39 hours a small number of new ring forms were visible, indicating that some merozoite release had occured, although most ring forms did not appear until 45 - 48 hours.
At six hour intervals the polypeptides synthesised during a 30 minute pulse with 35S-methionine were investigated. Maximal protein synthesis occured
during schizogeny, at36 hours. The time of synth
esis of many proteins was restricted during the
development cycle. One of the abundant proteins
synthesised only during schizogeny was the 1.95 x
105 MW protein.
When the proteins synthesised at each time
immunoprecipitated with pooled immune human serum. A clear pattern was observed. During the ring and trophozoite stages only two polypeptides of 1.6 x 105 MW and 0.71 x 105 MW were recognised by human immune serum and precipitated. During
schizogeny a number if polypeptides were recognised by human immune serum. The predominant species (larger than 0.3 x 105) had molecular weights of 0.37, OAO, 0A6, 0.62,0.72,0.80,0.84, 0.89, 1.04, 1.20. 1.34, 1 A6 (doublet), 1.78, 1.95,2.08,2.20 and 2.35 x 105. The synthesis of several of these proteins was at specific times during schizogeny. the 1.95 x 105 MW antigen was recognised by the immune serum and was synthesised throughout schizogeny.
The monoclonal antibody 89.1 also precipitated the 1.95 x 105 MW protein throughout schizogeny.
The processing of the protein subsequent to its synthesis, was investigated by performing immunoprecipitations on the solubilised pulse labelled material and on solubilised material from cells which had been pulse labelled and then chased with unlabelled methioninefor60 or 120 min.At30 h into the parasite development cycle (immature schizons) the 120 min chase resulted in no apparent shift in the
label to lower molecular weight bands. At42 h most of the radioactivity was incorporated during the
pulse record period into the 195,000MW band but
after 60 min chase the 1.53 and 1.50 x 105 MW bands were more apparent and the 0.83 x105 MW band appeared. After 120 min chase the 0.83 x 105 MW
band increased in intensity and some of the label was associated with a 0.6 x 105 MW polypeptide.
After 45 h of parasite development, processing of the 195,000 MW protein to its discrete fragments was moch more extensive during the chase period. (The immunoprecipitate at 48 h showed that some processing of the 195,000 MW protein through to the 60,000 MW fragment had occurred even within the 30 minuted pulse period). The onset of processing was concomitant with the appearance of new rings forms in the culture and, therefore, also with the
maturation of schizonts and release of infective
merozoites.
Example 10 Locallsation of the antigen associated
with P. flaciparum and cross-reaction
with a polyvalent serum raised against
the P. yoelAi antigen.
By IIF using acetone-fixed cells the antigen protein
was localised to the membrane of schizonts and
merozoites, the distribution being identical to the
antigen described in Example 4. Immunological
cross-reaction between the antigen of P. yoelii and
that of P. falciparum was demonstrated by raising
high tire polyvalentantiserum in mice to the P.
yoelii antigen, which had been prepared as
described in Example 2. When this antiserum was
assayed by immunofluorescence with P. yoelii
infected mouse cells, the pattern of fluorescent stain
ing was indistinguishable from that produced using
monoclonal antibody 25.i and the antiserum had a
litre of 1 in 20,000. When this antiserum was assayed against P. falciparum infected human red cells, it
gave a staining pattern identical to that of antibody
89.1, with a IIF titre of 1 in 1,600. This indicated an
immunological cross-reaction between the two anti
gens which is probably related to their structural
similarities.
Example 11 Vaccines
Vaccines for use in immunisation may be prepared
by conventional techniques with the following con
stitutents:
Formulation A
Antigen 2 mg
Physiological Saline to 1 ml
Formulation B
Antigen 1 mg Al hydrogel 1 mg
Physiological Saline to 1 ml
Claims (18)
1. A protein-inducing proteinaceous antigen of
parasites of the genusPlasmodium characterised
by:
(i) having an apparent molecular weight in the rangeof1.8x105to2.5x105; (ii) being associated with the membranes of the
erythrocytic schizont forms of the parasite; and
(iii) being processed intraethrocyticallyto dis
crete fragments possessing the same antigen
properties
and wherein the antigen, or the discrete fragments
thereof, are associated with the surface membrane
of the merozoite;
and functional derivatives thereof.
2. An antigen as claimed in claim 1 characterised in that the apparent molecular weight of the antigen
is from 1.90to2.30 x 105.
3. An antigen as claimed in claim 1 or claim 2 characterised in that the parasite is a humanPlasmodium parasite.
4. An antigen as claimed in claim 3 wherein the molecular weight is about 1.95 x 105.
5. An antigen as claimed in any one of claims 1 to 4 wherein the discrete fragments include fragments having a molecular weight of 0.3-0.4 x 05; 0.7-0.8 x 105 and 1.0-1.4 x 105 lower than that of the parent antigen.
6. An antigen as claimed in claim 4 wherein the discrete fragments include fragments having a molecularweightof1.53-1.5x105; 1.5x105; 1.10x 105 and 0.9 x105.
7. An antigen as claimed in any one of claims 1 to 6 wherein the parasite isPlasmodium falciparum.
8. An antigen as claimed in any one of claims 1 to 7 having an isoelectric point of about 5.8.
9. An antigen as claimed in any one of claims 1 to 8 wherein the discrete fragments include fragments having isoelectric points of about 5.2, about 6.0 and 6.2-6.5
10. An antigen as claimed in any one of claims 1 to 9 characterised in that it is prepared by the steps of:
(i) solubilising erythrocytes containing the schiz
ont form of a Plasmodium parasite;
(ii) contacting the solubilised materials with a
monoclonal antibody specific for the desired anti
gen to provide an antibody-antigen complex; and
(iii) recovering the antigen from the antibody
antigen complex.
11. An antigen as claimed in any one of claims 1 to 9 characterised in that it is prepared by a chemical or biological reproduction.
12. A method for the preparation of an antigen as defined in any one of claims 1 to 9 which method comprises:
(a) isolating the antigen from the erythrocytic schizontfrom of the parasite; or
(b) chemical or biological reproduction of the
antigen.
13. A vaccine which vaccine comprises an antigen as defined in any one of claims 1 to 11 together with a pharmaceutically acceptable carrier therefor.
14. A vaccine as claimed in claim 13 suitable for inducing immunity in humans to Plasmodium falciparum.
15. An anitgen, as defined in any one of claims 1 to 11, for use in inducing immunity in a susceptable vetebrate host
16. A method for inducing immunity to malaria in a susceptable vetebrate host comprising administration to the host of an antigen, as defined in any one of claims 1 toll.
17. An antigen as claimed in claim 15, in the form of a vaccine.
18. A method as claimed in claim 16 wherein the antigen is in the form of a vaccine.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8214624A GB2099300B (en) | 1981-05-21 | 1982-05-19 | Antigens from parasites of the genus plasmodium |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8115566 | 1981-05-21 | ||
GB8214624A GB2099300B (en) | 1981-05-21 | 1982-05-19 | Antigens from parasites of the genus plasmodium |
Publications (2)
Publication Number | Publication Date |
---|---|
GB2099300A true GB2099300A (en) | 1982-12-08 |
GB2099300B GB2099300B (en) | 1985-02-27 |
Family
ID=26279543
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB8214624A Expired GB2099300B (en) | 1981-05-21 | 1982-05-19 | Antigens from parasites of the genus plasmodium |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB2099300B (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2538253A1 (en) * | 1982-12-27 | 1984-06-29 | Pasteur Institut | Polypeptide fraction with an average molecular weight of 75,000, which induces protective antibodies to malaria parasites, and immunogenic compositions containing them |
EP0112784A1 (en) * | 1982-12-27 | 1984-07-04 | Pasteur Institut | Polypeptidic fractions inducing protective antibodies against malaria parasites, and immunogenic compositions containing them |
WO1984002917A1 (en) * | 1983-01-28 | 1984-08-02 | Inst Medical W & E Hall | EXPRESSION OF PLASMODIUM FALCIPARUM POLYPEPTIDES FROM CLONED cDNA |
FR2550942A1 (en) * | 1983-08-25 | 1985-03-01 | Ambroise Thomas Pierre | VACCINE AGAINST MALARIA AND METHOD FOR PREPARING THE SAME |
JPS60500478A (en) * | 1983-01-28 | 1985-04-11 | ザ・ワルタ−・アンド・エリザ・ホ−ル・インスティテュ−ト・オブ・メディカル・リサ−チ | Expression of P. falciparum polypeptide from cloned cDNA |
FR2556971A2 (en) * | 1983-12-21 | 1985-06-28 | Pasteur Institut | Polypeptide fractions which induce protective antibodies to malaria parasites, and immunogenic compositions containing them |
WO1986006075A1 (en) * | 1985-04-11 | 1986-10-23 | The Walter And Eliza Hall Institute Of Medical Res | Highly repetitive antigens of plasmodium falciparum |
US4643896A (en) * | 1983-06-10 | 1987-02-17 | Otsuka Pharmaceutical Co., Ltd. | Malaria associated antigen and preparing process thereof |
FR2589062A1 (en) * | 1985-10-28 | 1987-04-30 | Inst Nat Sante Rech Med | ANTIGENS OBTAINED FROM THE INTRAERYTHROCYTE PHASE OF PLASMODIUM FALCIPARUM, THEIR PURIFICATION, THEIR ASSAY AND THEIR ANTIBODY, AND THE VACCINES AGAINST MALARIA CONTAINING THEM |
US4767622A (en) * | 1983-08-19 | 1988-08-30 | University Of Illinois | Method and materials for development of immunological responses protective against malarial infection |
US4859464A (en) * | 1982-02-17 | 1989-08-22 | Antonio Lawrence E | Method for the purification of parasite antigenic factors |
EP0447808A2 (en) * | 1983-01-28 | 1991-09-25 | Saramane Pty. Ltd. | Expression of Plasmodium falciparum polypeptides from cloned cDNA |
EP0153188B1 (en) * | 1984-02-21 | 1991-10-09 | National Research Development Corporation | Improvements in or relating to the production of malaria vaccines |
US5231168A (en) * | 1988-09-16 | 1993-07-27 | Statens Seruminstitut | Malaria antigen |
US7931908B2 (en) | 2007-02-23 | 2011-04-26 | Philadelphia Health Education Corporation | Chimeric MSP-based malaria vaccine |
-
1982
- 1982-05-19 GB GB8214624A patent/GB2099300B/en not_active Expired
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4859464A (en) * | 1982-02-17 | 1989-08-22 | Antonio Lawrence E | Method for the purification of parasite antigenic factors |
EP0112784A1 (en) * | 1982-12-27 | 1984-07-04 | Pasteur Institut | Polypeptidic fractions inducing protective antibodies against malaria parasites, and immunogenic compositions containing them |
WO1984002472A1 (en) * | 1982-12-27 | 1984-07-05 | Pasteur Institut | Polypeptidic fractions inducing protection antibodies against parasites of paludism, and immunizing compositions containing them |
WO1984002471A1 (en) * | 1982-12-27 | 1984-07-05 | Pasteur Institut | Polypeptidic fractions inducing protective antibodies against mallaria parasites and immunogenic compositions containing them |
US5032397A (en) * | 1982-12-27 | 1991-07-16 | Institut Pasteur | Polypeptidic fractions inducing protective antibodies against malaria parasites and immunogenic compositions |
FR2538253A1 (en) * | 1982-12-27 | 1984-06-29 | Pasteur Institut | Polypeptide fraction with an average molecular weight of 75,000, which induces protective antibodies to malaria parasites, and immunogenic compositions containing them |
GB2143830A (en) * | 1983-01-28 | 1985-02-20 | Inst Medical W & E Hall | Expression of plasmodium falciparum polypeptides from cloned cdna |
WO1984002917A1 (en) * | 1983-01-28 | 1984-08-02 | Inst Medical W & E Hall | EXPRESSION OF PLASMODIUM FALCIPARUM POLYPEPTIDES FROM CLONED cDNA |
EP0447808A3 (en) * | 1983-01-28 | 1991-11-06 | Saramane Pty. Ltd. | Expression of plasmodium falciparum polypeptides from cloned cdna |
EP0447808A2 (en) * | 1983-01-28 | 1991-09-25 | Saramane Pty. Ltd. | Expression of Plasmodium falciparum polypeptides from cloned cDNA |
JPS60500478A (en) * | 1983-01-28 | 1985-04-11 | ザ・ワルタ−・アンド・エリザ・ホ−ル・インスティテュ−ト・オブ・メディカル・リサ−チ | Expression of P. falciparum polypeptide from cloned cDNA |
US4643896A (en) * | 1983-06-10 | 1987-02-17 | Otsuka Pharmaceutical Co., Ltd. | Malaria associated antigen and preparing process thereof |
US4767622A (en) * | 1983-08-19 | 1988-08-30 | University Of Illinois | Method and materials for development of immunological responses protective against malarial infection |
FR2550942A1 (en) * | 1983-08-25 | 1985-03-01 | Ambroise Thomas Pierre | VACCINE AGAINST MALARIA AND METHOD FOR PREPARING THE SAME |
FR2556971A2 (en) * | 1983-12-21 | 1985-06-28 | Pasteur Institut | Polypeptide fractions which induce protective antibodies to malaria parasites, and immunogenic compositions containing them |
EP0153188B1 (en) * | 1984-02-21 | 1991-10-09 | National Research Development Corporation | Improvements in or relating to the production of malaria vaccines |
WO1986006075A1 (en) * | 1985-04-11 | 1986-10-23 | The Walter And Eliza Hall Institute Of Medical Res | Highly repetitive antigens of plasmodium falciparum |
EP0223665A1 (en) * | 1985-10-28 | 1987-05-27 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Antigens obtained from the intraerythrocytic stage of Plasmodium falciparum, their purification, their dosage and that of their antibodies, and malaria vaccines containing them |
FR2589062A1 (en) * | 1985-10-28 | 1987-04-30 | Inst Nat Sante Rech Med | ANTIGENS OBTAINED FROM THE INTRAERYTHROCYTE PHASE OF PLASMODIUM FALCIPARUM, THEIR PURIFICATION, THEIR ASSAY AND THEIR ANTIBODY, AND THE VACCINES AGAINST MALARIA CONTAINING THEM |
US5231168A (en) * | 1988-09-16 | 1993-07-27 | Statens Seruminstitut | Malaria antigen |
US7931908B2 (en) | 2007-02-23 | 2011-04-26 | Philadelphia Health Education Corporation | Chimeric MSP-based malaria vaccine |
US8153140B2 (en) | 2007-02-23 | 2012-04-10 | Philadelphia Health And Education Corporation | Chimeric MSP-based malaria vaccine |
Also Published As
Publication number | Publication date |
---|---|
GB2099300B (en) | 1985-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0071705B1 (en) | Protozoal antigen | |
Holder et al. | Immunization against blood-stage rodent malaria using purified parasite antigens | |
Kilejian | Stage-specific proteins and glycoproteins of plasmodium falciparum: identification of antigens unique to schizonts and merozoites. | |
Coppel et al. | Isolate-specific S-antigen of Plasmodium falciparum contains a repeated sequence of eleven amino acids | |
McBride et al. | Polymorphism of a high molecular weight schizont antigen of the human malaria parasite Plasmodium falciparum. | |
Howard et al. | Secretion of a malarial histidine-rich protein (Pf HRP II) from Plasmodium falciparum-infected erythrocytes. | |
Hinterberg et al. | Plasmodium falciparum:-The Pf332 Antigen Is Secreted from the Parasite by a Brefeldin A-Dependent Pathway and Is Translocated to the Erythrocyte Membrane via the Maurer′ s Clefts | |
CA1196282A (en) | Protozoal antigen | |
GB2099300A (en) | Antigens from parasites of the genus plasmodium | |
Pang et al. | Antibodies reactive with the N-terminal domain of Plasmodium falciparum serine repeat antigen inhibit cell proliferation by agglutinating merozoites and schizonts | |
Langer et al. | Cryptosporidium parvum apical complex glycoprotein CSL contains a sporozoite ligand for intestinal epithelial cells | |
Barnwell et al. | Plasmodium vivax, P. cynomolgi, andP. knowlesi: Identification of Homologue Proteins Associated with the Surface of Merozoites | |
Hui et al. | Characterization of a Plasmodium falciparum polypeptide associated with membrane vesicles in the infected erythrocytes | |
US4978621A (en) | Merozoite surface antigens | |
Feng et al. | Pfs2400 can mediate antibody-dependent malaria transmission inhibition and may be the Plasmodium falciparum 11.1 gene product. | |
EP0153188A1 (en) | Improvements in or relating to the production of malaria vaccines | |
Pratt et al. | Monoclonal antibodies recognizing determinants specific for the promastigote stage of Leishmania mexicana | |
US5116755A (en) | Asexual blood stage antigens of plasmodium falciparum which encode a rhoptry protein | |
US4835259A (en) | Merozoite surface glycoproteins | |
Da Silva et al. | Plasmodium falciparum polypeptides released during in vitro cultivation | |
Barnes et al. | Plasmodium falciparum: D260, an intraerythrocytic parasite protein, is a member of the glutamic acid dipeptide-repeat family of proteins | |
Deans | Protective antigens of bloodstage Plasmodium knowlesi parasites | |
Masuda et al. | Monoclonal anti-gametocyte antibodies identify an antigen present in all blood stages of Plasmodium falciparum | |
US4897354A (en) | Monoclonal antibody-specific merozoite antigens | |
Boyle et al. | Intraerythrocytic development and antigenicity of Plasmodium falciparum and comparison with simian and rodent malaria parasites |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
732E | Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977) | ||
PE20 | Patent expired after termination of 20 years |
Effective date: 20020518 |